Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28493449 | 0.83 | HSD17B10 (0.53) | HSD17B10PIK3CDGAATSHR | |
| SCHEMBL24672241 | 0.83 | HSD17B10 (0.63) | HSD17B10PIK3CD | |
| SCHEMBL28902590 | 0.83 | HSD17B10 (0.63) | HSD17B10PIK3CD | |
| SCHEMBL24672946 | 0.83 | HSD17B10 (0.63) | HSD17B10PIK3CD | |
| SCHEMBL21814634 | 0.81 | HSD17B10 (0.61) | HSD17B10PIK3CD | |
| SCHEMBL20438377 | 0.80 | PIK3CD (0.61) | PIK3CDCYP2D6SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2001262 | 0.80 | — | — | |
| SCHEMBL24209746 | 0.80 | PIK3CD (0.61) | PIK3CDCYP2D6SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1621691 | 0.80 | PIK3CD (0.61) | PIK3CDCYP2D6SMN1; SMN2NPC1RAB9A | |
| SCHEMBL23842299 | 0.78 | HSD17B10 (0.44) | HSD17B10PIK3CDSMN1; SMN2GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2687516-A1 | Inhibitors of C-FMS Kinase | Janssen Pharmaceutica N.V. (BE) | 2014-01-22 | — | — | EP | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1663999-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES, LTD. (IN) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021515-A2 | INHIBITORS OF PHOSPHODIESTERASE TYPE-IV | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | HSD17B10 910/4885PIK3CD 2207/4885CYP2D6 560/4885 |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | HSD17B10 2560/4885PIK3CD 4640/4885CYP2D6 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.